Personalized Treatment Service Online for Individuals with Headache & Migraines 

  • Cluster headache
  • Coronavirus
  • COVID-19
  • Headache
  • Migraine
  • Telemedicine

Individuals with headaches and migraines have the ability to manage their attacks with comprehensive online consultations and ongoing check-ins, personalized treatment plans, and home delivery of medication using a new telemedicine service (Nurx; Gilead Sciences, San Francisco, CA). The service also eliminates the need to make an in-person appointment, travel to a clinic, or wait in line at the pharmacy. All health insurance is accepted and offers transparent pricing for those without coverage. 

The service is available for individuals who experience occasional or chronic tension headaches and migraines. With a yearly payment of $60 per year individuals will receive inclusive online medical consultation, video exam, daily headache tracker, and regular check-ins with a trained and licensed medical provider. The service also provides home delivery of medication with refills.
This service is being introduced in the midst of the COVID-19 pandemic when people who experience migraine attacks face several challenges seeing their in-person providers, may be concerned about risk of exposure at the pharmacy, and often experience a higher level of stress and anxiety, which are common triggers for headaches and migraine attacks. According to a recent survey, 84% of individuals who experience migraines said the pandemic has affected their migraine management, including reduced access to medication and difficulty scheduling appointments.

"Many of our current patients experience migraines, and we look forward to providing them with a comprehensive and personalized treatment plan for a healthcare issue that can make a significant impact on their wellbeing," said Nurx chief executive officer Varsha Rao. "The COVID-19 pandemic has only exacerbated access issues for care and treatment, and we are committed to ensuring we can address our patients' health needs while they remain safely at home." 

Anticholinergics May be Associated With Increased Risk of Mild Cognitive Impairment

Previous News Article

Lacosamide Lowers Risk of Second Primary Generalized Tonic-Clonic Seizure in Clinical Trials

Next News Article
This Month's Issue
Epilepsy and Autism

Alyssa R. Rosen, MD

Movement Disorders Moment: Treatment Approaches to Cervical Dystonia

Zehra Farzal, MD; Guillaume Lamotte MD, MSc; Elizabeth Mundel, MD; Laxman B. Bahroo, DO; and Fernando L. Pagan, MD